154 related articles for article (PubMed ID: 38597068)
1. Heart failure management with β-blockers: can we do better?
de Oliveira MT; Baptista R; Chavez-Leal SA; Bonatto MG
Curr Med Res Opin; 2024; 40(sup1):43-54. PubMed ID: 38597068
[TBL] [Abstract][Full Text] [Related]
2. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
3. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
Nochioka K; Sakata Y; Shimokawa H
Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
[TBL] [Abstract][Full Text] [Related]
5. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
6. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
[TBL] [Abstract][Full Text] [Related]
7. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
[TBL] [Abstract][Full Text] [Related]
8. The current best drug treatment for hypertensive heart failure with preserved ejection fraction.
Rist A; Sevre K; Wachtell K; Devereux RB; Aurigemma GP; Smiseth OA; Kjeldsen SE; Julius S; Pitt B; Burnier M; Kreutz R; Oparil S; Mancia G; Zannad F
Eur J Intern Med; 2024 Feb; 120():3-10. PubMed ID: 37865559
[TBL] [Abstract][Full Text] [Related]
9. Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.
Kim HJ; Jo SH; Lee MH; Seo WW; Choi JO; Ryu KH
Adv Ther; 2020 Sep; 37(9):3839-3849. PubMed ID: 32676928
[TBL] [Abstract][Full Text] [Related]
10. What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence.
Sevre K; Rist A; Wachtell K; Devereux RB; Aurigemma GP; Smiseth OA; Kjeldsen SE; Julius S; Pitt B; Burnier M; Kreutz R; Oparil S; Mancia G; Zannad F
Am J Hypertens; 2024 Jan; 37(1):1-14. PubMed ID: 37551929
[TBL] [Abstract][Full Text] [Related]
11. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
[TBL] [Abstract][Full Text] [Related]
12. Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand.
Teng TK; Tay WT; Ouwerkerk W; Tromp J; Richards AM; Gamble G; Greene SJ; Yiu KH; Poppe K; Ling LH; Lund M; Sim D; Devlin G; Loh SY; Troughton R; Ren QW; Jaufeerally F; Lee SGS; Tan RS; Soon DKN; Leong G; Ong HY; Yeo DPS; Lam CSP; Doughty RN
ESC Heart Fail; 2023 Apr; 10(2):1280-1293. PubMed ID: 36722315
[TBL] [Abstract][Full Text] [Related]
13. Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
Ouwerkerk W; Teng TK; Tromp J; Tay WT; Cleland JG; van Veldhuisen DJ; Dickstein K; Ng LL; Lang CC; Anker SD; Zannad F; Hung CL; Sawhney JPS; Naik A; Shimizu W; Hagiwara N; Wander GS; Anand I; Richards AM; Voors AA; Lam CSP
Eur J Heart Fail; 2020 Aug; 22(8):1472-1482. PubMed ID: 32583922
[TBL] [Abstract][Full Text] [Related]
14. The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure.
Pugliese NR; Masi S; Taddei S
Heart Fail Rev; 2020 Jan; 25(1):31-42. PubMed ID: 31512149
[TBL] [Abstract][Full Text] [Related]
15. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
Vaduganathan M; Claggett BL; Jhund PS; Cunningham JW; Pedro Ferreira J; Zannad F; Packer M; Fonarow GC; McMurray JJV; Solomon SD
Lancet; 2020 Jul; 396(10244):121-128. PubMed ID: 32446323
[TBL] [Abstract][Full Text] [Related]
16. Beta-blocker use in patients with heart failure with preserved ejection fraction and sinus rhythm.
Formiga F; Chivite D; Nuñez J; Moreno García MC; Manzano L; Arévalo-Lorido JC; Cerqueiro JM; García Campos Á; Trullàs JC; Montero-Pérez-Barquero M;
Rev Port Cardiol; 2022 Oct; 41(10):853-861. PubMed ID: 36207068
[TBL] [Abstract][Full Text] [Related]
17. Management of Heart Failure Patient with CKD.
Banerjee D; Rosano G; Herzog CA
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1131-1139. PubMed ID: 33495289
[TBL] [Abstract][Full Text] [Related]
18. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
19. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
[TBL] [Abstract][Full Text] [Related]
20. Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction.
Park CS; Park JJ; Mebazaa A; Oh IY; Park HA; Cho HJ; Lee HY; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
J Am Heart Assoc; 2019 Mar; 8(6):e011077. PubMed ID: 30845873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
